{"organizations": [], "uuid": "55a931d32234bb860ad226e1e300c67f1c012bb8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180214.html", "section_title": "Archive News &amp; Video for Wednesday, 14 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-veru-q1-loss-per-share-008/brief-veru-q1-loss-per-share-0-08-idUSASB0C5M1", "country": "US", "domain_rank": 408, "title": "BRIEF-Veru Q1 Loss Per Share $0.08", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.014, "site_type": "news", "published": "2018-02-14T19:36:00.000+02:00", "replies_count": 0, "uuid": "55a931d32234bb860ad226e1e300c67f1c012bb8"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-veru-q1-loss-per-share-008/brief-veru-q1-loss-per-share-0-08-idUSASB0C5M1", "ord_in_thread": 0, "title": "BRIEF-Veru Q1 Loss Per Share $0.08", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters) - veru inc", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 14 (Reuters) - Veru Inc:\n* VERU REPORTS FISCAL 2018 FIRST-QUARTER FINANCIAL RESULTS\n* Q1 LOSS PER SHARE $0.08 * Q1 REVENUE $2.6 MILLION VERSUS $3.2 MILLION * REMAIN ON TRACK TO FILE WITH FDA COMPANYâ€˜S FIRST NDA FOR TAMSULOSIN DRS IN 2018\n* PLAN TO SUBMIT TWO ADDITIONAL NDAS IN 2019 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-14T19:36:00.000+02:00", "crawled": "2018-02-15T20:57:37.009+02:00", "highlightTitle": ""}